Healthcare Industry News: Dimebon
News Release - August 8, 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical DevelopmentSAN FRANCISCO, Aug. 8 (HSMN NewsFeed) -- Medivation, Inc. (Nasdaq: MDVN ) today announced that it has appointed Robert Elfont, M.D., Ph.D., as vice president of clinical development. He is responsible for directing the Company's clinical development program for Dimebon(TM), its lead product candidate, in Alzheimer's disease.
"Rob's extensive experience in the pharmaceutical industry, particularly in neurologic disorders, and his expertise in leading clinical trials will be invaluable to Medivation as we advance Dimebon through clinical development," said David Hung, M.D., president and chief executive officer of Medivation. "His addition to our senior management team comes at a pivotal time as we recently completed our 12-month Phase 2 trial of Dimebon in Alzheimer's disease showing strongly positive results and are moving forward with plans to initiate our Phase 3 clinical program next year."
Dr. Elfont joined Medivation from Roche Pharmaceuticals, where he served as clinical research and licensing liaison, neuroscience, and was responsible for developing strategy from lead compound optimization through entry into human and proof of concept trials. He has expertise in the therapeutic areas of Alzheimer's disease, schizophrenia, depression, pain and multiple sclerosis. Dr. Elfont previously worked for Pfizer Global Research & Development, most recently as a director in Clinical Research & Development/CNS, and for Teva Neuroscience, as U.S. director of multiple sclerosis projects. At these companies, he gained clinical trial experience in all phases of drug development. Before joining the pharmaceutical industry, Dr. Elfont was an assistant professor of neurology at Johns Hopkins University School of Medicine and later at Drexel University College of Medicine.
Dr. Elfont is an author of more than 20 scientific publications. He earned an M.D. and Ph.D. in neuroanatomy from the University of Rochester School of Medicine and Dentistry and completed a residency in neurology at Johns Hopkins Hospital. He received additional training as a research student in physiological psychology at the University of Cambridge, and was a postdoctoral fellow in neuroimmunology and neurovirology at Johns Hopkins University School of Medicine. He received an A.B., magna cum laude, from the University of Pennsylvania. Dr. Elfont is Board-certified in neurology.
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone- refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.